

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number
WO 2005/030265 A2

(51) International Patent Classification⁷: **A61K 49/00**

(21) International Application Number:
PCT/NO2004/000286

(22) International Filing Date:
28 September 2004 (28.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20034351 29 September 2003 (29.09.2003) NO

(71) Applicant (for all designated States except US): **AMERSHAM HEALTH AS** [NO/NO]; Intellectual Property Dept., P.O. Box 4220 Nydalen, Nycoveien 1-2, N-0401 Oslo (NO).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KLAVENESS, Jo** [NO/NO]; Midtåsen 5, N-1166 Oslo (NO). **JOHANNESEN, Edvin** [NO/NO]; Amersham Health AS, P.O. Box 4220 Nydalen, Nycoveien 1-2, N-0401 Oslo (NO). **TOLLESHAUG, Helge** [NO/NO]; Amersham Health AS, P.O. Box 4220 Nydalen, Nycoveien 1-2, N-0401 Oslo (NO).

(74) Agents: **WULFF, Marianne, Weiby et al.**; Amersham Health AS, P.O. Box 4220 Nydalen, Nycoveien 1-2, N-0401 Oslo (NO).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/030265 A2

(54) Title: OPTICAL IMAGING OF ENDOMETRIOSIS

(57) Abstract: The invention provides contrast agents for optical imaging of endometriosis in patients. The contrast agent may be used in diagnosis of endometriosis, for follow-up of progress in disease development, and for follow-up of treatment of endometriosis. Further, the invention provides methods for optical imaging of endometriosis.

Optical imaging of endometriosis

5 Field of the invention

The present invention provides contrast agents for optical imaging of endometriosis in patients. The contrast agents may be used in diagnosis of endometriosis, for follow up of progress in disease development, and for follow up of treatment of endometriosis.

10

The present invention also provides new methods of optical imaging of endometriosis in patients, for diagnosis, and for follow up of disease development and treatment of endometriosis.

15 Description of related art

Endometriosis is a disorder that may be painful. The disorder is characterized by endometrial tissue being present in other organs than the endometrium. Typical organs where endometrial tissue may be present in endometriosis include, in addition to endometrium, the abdominal wall and the outer surfaces of organs in the abdomen including lower bowel, ovaries and fallopian tubes. Endometriosis is a disease that affects several percent of the fertile female population. Some patients are asymptomatic whereas others have symptoms such as chronic pain, dysmenorrhoea (menstrual disturbances). Even mild endometriosis may result in infertility or reduced fertility.

25

The aims of treatment of a patient with endometriosis often include relief of pain and elimination of endometrial tissue outside the endometrium. Current treatments of endometriosis include surgery and/or drug treatment. Drugs used in endometriosis are drugs that suppress the activity of the ovaries and slow down the growth of endometrial cells.

30

Methods for diagnosis of endometriosis include *in vitro* methods using immunoassays, for instance CA-125 and endometrial antibodies, laparoscopic examinations and various medical imaging techniques such as computer tomography, ultrasound and MRI. *In vitro* assays are not sufficiently sensitive for diagnosis of endometriosis. In general, medical literature reports varying degrees of success in using medical imaging for diagnosing endometriosis. The best imaging

35

method today is probably MRI. However, the MR signal from endometriotic tissue varies considerably and it is not possible to distinguish endometriosis from other diseases in the same organ or organ system.

5 Various radiolabelled monoclonal antibodies or fragments thereof have been evaluated for diagnosis of endometriosis, but again these agents show low sensitivity and/or low specificity.

10 The most promising diagnostic tool today for diagnosis of endometriosis is laparoscopy. However, this method has its limitation in early diagnosis of endometriosis and for follow up therapy of endometriosis.

15 WO 95/13821 claims a method for diagnosis of endometriosis based on assaying for $\beta 3$ integrin in a sample of endometriotic tissue using a monoclonal antibody specific for $\beta 3$ integrins. There is no description of its use *in vivo*.

20 US 6,387,629 claims that cathepsin S expression is upregulated during endometriosis. The patent document focuses on *in vitro* assays to determine cathepsin S, however, there are claims related to *in vivo* use and specific claims on radioisotopes and paramagnetic compounds. There is no description of optical imaging methods *in vivo*. The targeting vector has a polynucleotide of at least 7 to about 50 nucleotides in length.

25 WO 99/63116 relates to the use of prothymosin in the diagnosis and treatment of endometriosis. The invention is based on the observation that prothymosin expression is upregulated in endometriosis. The application focuses on diagnosis of endometriosis based on prothymosin in tissue samples such as endometriotic tissue, blood and urine, however, there are claims related to *in vivo* use and specific claims related to radioisotopes and MRI.

30 US 5,328,826 relates to immunochemical detection of human uterine endometrial cancer cells and not endometriosis *per se*.

35 WO 93/20810 relates to compositions comprising a precursor of PpIX for detecting and treating malignant and non-malignant tissue including diseases in the endometrium. There is no description of specific use for diagnosing endometriosis.

WO 00/59547 and US 6,540,980 relates to kits for detecting or treating endometriosis comprising an eosinophil peroxidase-binding component. The targeting agent might according to the claims be labeled with a fluorescent label and might be used *in vivo*. The targeting agents are antibodies and fragments thereof. There is no disclosure of 5 low molecular weight compounds.

WO 00/47739 relates to polypeptide antigens for detection of auto-antibodies in endometriosis patients. The diagnostic use of these polypeptide antigens includes any *in vitro* assay and does not disclose *in vivo* use.

10 WO 00/25789 discloses a method for preventing and treating endometriosis and other related diseases and is comprised of administering to a patient a phenyl-protein transferase inhibitor. The invention is not related to diagnosis or to low molecular weight compounds.

15 US 5,618,680 discloses a method for diagnosing endometriosis based on ligands which specifically binds a Major Histocompatibility Complex (MHC)-Class I antigen. The document does not discuss *in vivo* imaging.

20 US 5,380,317 relates to a medical device applying localised high intensity light and heat for destruction of the endometrium. The document does not relate to contrast agents.

WO 97/06797 relates to endometrial ablation using photodynamic therapy.

25 As pointed out there is still a challenge to diagnose and treat endometriosis. There is still need for improved diagnostic methods, especially for diagnosis of endometriosis in an early stage with good reliability. We have surprisingly discovered that the use of optical imaging methods and new contrast agents fulfill these requirements.

30 **Summary of the invention**
In view of the needs of the art the present invention provides an optical imaging contrast agent with affinity for an abnormally expressed biological target associated with endometriosis.

35 The invention is also described in the claims.

The following definitions will be used throughout the document:

Endometriotic tissue: The aberrant occurrence of tissue that more or less perfectly resembles the endometrium in various locations in the pelvic cavity.

5

Abnormally expressed target: A target that is either overexpressed or downregulated in endometriotic tissue.

Overexpressed target: A receptor, an enzyme or another molecule or chemical entity
10 that is present in a higher amount (upregulated) in endometriotic tissue than in normal tissue.

Downregulated target: A receptor, an enzyme or another molecule or chemical entity that is present in a lower amount in endometriotic tissue than in normal tissue.

15

Detailed description of the invention

A first aspect of the present invention is an optical imaging contrast agent for imaging of endometriosis. By the term optical imaging contrast agent, or just contrast agent, we mean a molecular moiety used for enhancement of image contrast *in vivo*
20 comprising at least one moiety that interacts with light in the ultraviolet, visible or near infrared part of the electromagnetic spectrum.

The contrast agent has affinity for an abnormally expressed target associated with endometriosis. By abnormally expressed, is meant that the target is either
25 overexpressed or downregulated.

Endometriotic tissue containing a downregulated target may be identified by a low amount of bound contrast agent compared to normal tissue. In this situation, the amount of contrast agent should be less than 50 % of that in normal tissue,
30 preferably less than 10 %.

Preferably, the contrast agent, according to the present invention, has affinity for an overexpressed target associated with endometriosis. Preferred targets are those targets that are more than 50 % abundant in endometriotic tissue than in surrounding
35 tissue. More preferred targets are those targets that are more than two times abundant in endometriotic tissue than in surrounding tissue. The most preferred

targets are those targets that are more than 5 times abundant in endometriotic tissue than in surrounding tissue.

Relevant groups of targets are receptors, enzymes, nucleic acids, proteins, lipids,
5 and other macromolecules such as for example lipoproteins and glycoproteins. The
targets may be located in the vascular system, in the extracellular space, associated
with cell membranes or located intracellularly.

10 The following biological targets are preferred targets for contrast agents for optical
imaging of endometriosis:

Overexpressed targets:

Angiogenesis targets:

15 Vascular endothelial growth factor, integrins (β_1 -integrins, integrin alpha_v beta₃) and
matrix metalloproteases.

Mainly upregulated during the secretory phase of the menstrual cycle: matrix
metallopeptidase 7

20

Receptors:

Estrogen receptors; progesterone receptors, interleukin-1 receptor.

Mainly upregulated during the secretory phase of the menstrual cycle: galectin 6-

25 binding protein.

Adhesion molecules:

ICAM-1, CD44; cadherins such as E-cadherin, N-cadherin, P-cadherin and cadherin
11.

30

Extracellular matrix proteins:

Tenascin, osteopontin, fibulin 1, proteoglycan 4.

Enzymes:

35 Endothelial nitric oxide synthase, cathepsin H, cathepsin S, superoxide dismutase,
aromatase, protein kinases, especially extracellular signal regulated kinase (ERK),
HMG CoA reductase, Tyrosine kinases, reductase, protein farnesyltransferase, 17 β -

hydroxysteroid dehydrogenase, cyclooxygenase-2, Xanthine oxidase, membrane-associated neutral endopeptidase (CD10), catalase and MMPs.

Mainly upregulated during the proliferative phase of the menstrual cycle:

5 ribonuclease, phytanoyl-CoA hydroxylase, pyrroline 5-carboxylate reductase.

Mainly upregulated during the secretory phase of the menstrual cycle:

palmitoyl-protein thioesterase 1, ubiquitin-conjugating enzyme E2N, malate

dehydrogenase 1, aldehyde dehydrogenase 1, sterol-C5-desaturase, IGF-binding

10 serine protease, α-L-fucosidase, glycogenin.

Oncogenes and neoplasia-related proteins:

c-myc, c-erb-B2, nm23, hepatocellular carcinoma-associated antigen 112, acute

lymphoblastic leukemia antigen (CD10) and p53.

15

Mainly upregulated during the proliferative phase of the menstrual cycle: Src-like adaptor protein, Ras suppressor protein 1.

Mainly upregulated during the secretory phase of the menstrual cycle:

20 neuroblastoma suppressor 1.

Cytokines and similar signal proteins:

Interleukin-6, monocyte chemotactic protein-1, transforming growth factor, IgE-dependent histamine-releasing factor

25

Mainly upregulated during the proliferative phase of the menstrual cycle:

Small inducible cytokine A4.

Proteins of the immune system:

30 C3 complement, complement component 1S subcomponent, major histocompatibility antigens, class II, particularly DP α1, DQ α1, DR α, DQ β1, DR β and major histocompatibility complex class 1C, Ig-lambda light chain, Ig H chain G-E-A region gamma-2 constant region.

35 Mainly upregulated during the secretory phase of the menstrual cycle:

Complement component 3, properdin, complement component 1s, complement component 1r, complement component 2, Major histocompatibility antigens (class I F).

5 **Cytoskeletal proteins:**

β-actin, α₂ actin, vimentin.

Mainly upregulated during the proliferative phase of the menstrual cycle:

Actin-related protein 2/3 complex (subunit 1A), myosin regulatory light chain 2

10 (smooth muscle isoform), tropomyosin 1, β-actin.

Transport proteins:

Folate binding proteins, haptoglobin.

15 Mainly upregulated during the proliferative phase of the menstrual cycle:

lactotransferrin, cellular retinol-binding protein, lysosomal H⁺-transporting ATP-ase, potassium voltage-gated channel (shaker-related subfamily, member 5).

Mainly upregulated during the secretory phase of the menstrual cycle: heme-binding

20 protein.

Ribosomal proteins:

40S ribosomal protein S23.

Mainly upregulated during the proliferative phase of the menstrual cycle:

25 ribosomal protein L11, ribosomal protein S11, ubiquitin A-52 residue ribosomal protein fusion product 1.

Mainly upregulated during the secretory phase of the menstrual cycle:

ribosomal protein S23.

30 **Others:**

CD14 (lipopolysaccharide binding protein), CD43, CD45, endoglin, Endometrial bleeding-associated factor (LEFTY-A), arachidonate 5-lipoxygenase-activating protein.

35 Mainly upregulated during the proliferative phase of the menstrual cycle:

CDC10, S100 calcium-binding protein A13, tax interaction protein 1, GDP dissociation inhibitor 2, chimaerin 2.

Mainly upregulated during the secretory phase of the menstrual cycle:

5 CCAAT/enhancer binding protein, epididymal secretory protein, low-density lipoprotein-related protein-associated protein 1, cyclin D2, caveolin 1, cellular repressor of E1A-stimulated genes, G-rich RNA sequence binding factor 1.

Downregulated targets:

10 **Angiogenesis targets:**

Mainly downregulated during the proliferative phase of the menstrual cycle:
cysteine-rich angiogenic inducer.

Receptors:

15 Arginine vasopressin receptor 1A.

Mainly downregulated during the proliferative phase of the menstrual cycle:
G protein-coupled receptor RDC1.

Mainly downregulated during the secretory phase of the menstrual cycle:

20 formyl peptide receptor-like 1.

Adhesion molecules:

Mainly downregulated during the secretory phase of the menstrual cycle:

R-cadherin (cadherin 4), vascular endothelial junction-associated molecule.

25

Extracellular matrix proteins:

Mainly downregulated during the proliferative phase:

Laminin β 3.

30 Mainly downregulated during the secretory phase of the menstrual cycle:
crystallin α B.

Enzymes:

Arginase, mitogen-activated protein kinase kinase 3, cytochrome P450 2C18,

35 glycerol kinase, serum/gucocorticoid regulated kinase, long-chain fatty acid coenzyme A ligase 5, RNA helicase.

Mainly downregulated during the proliferative phase of the menstrual cycle:
carbonic anhydrase XII, pantetheinase (vanin 1).

Mainly downregulated during the secretory phase of the menstrual cycle:

5 glutathione peroxidase, monoamine oxidase, histone deacetylase,
phosphatidylserine decarboxylase, serine/threonine kinase 19, myo-inositol-
monophosphatase, glycogen phosphorylase, alkylglycerone phosphate synthase,
creatine kinase, phenylalanyl-tRNA synthetase β-subunit.

10 **Oncogenes and neoplasia-related proteins:**

Retinoblastoma-binding protein 6, RAS-dexamethason-induced 1.

Mainly downregulated during the proliferative phase of the menstrual cycle:
N-myc (downstream regulated)

15 Mainly downregulated during the secretory phase of the menstrual cycle:
growth arrest and DNA-damage-inducible protein-α, retinoblastoma-like 1

Cytokines and similar signal proteins:

lymphotoxin-α, neurotensin

20 Mainly downregulated during the proliferative phase of the menstrual cycle:
cytokine subfamily A member 20.

Mainly downregulated during the secretory phase of the menstrual cycle:

25 cytokine subfamily B member 14, colony-stimulating factor 3, interferon-related
developmental regulator 1.

Proteins of the immune system:

Mainly downregulated during the secretory phase of the menstrual cycle:

30 C4-binding protein-α.

Cytoskeletal proteins:

Mainly downregulated during the secretory phase of the menstrual cycle:

Actin γ2, actinin α4, plectin 1.

35

Transport proteins:

Mainly downregulated during the secretory phase of the menstrual cycle:

solute carrier family 3 member 1.

Ribosomal proteins:

Mainly downregulated during the secretory phase of the menstrual cycle:
mitochondrial ribosomal protein S2.

5

Others:

Kruppel-like factor 5, GATA-binding protein 2, heat shock protein 105 kDa, non-histone chromosomal proteins I and Y, oviducal glycoprotein 1 (oviductin), DNAJ-like HSP 2, DNAJ (Hsp40) homolog subfamily B member 1, stromal antigen 2, heat shock protein 70, heat shock protein 27.

10

Mainly downregulated during the proliferative phase of the menstrual cycle:

Zinc finger protein 216, adipose differentiation-related protein, heterogeneous nuclear ribonucleoprotein A1, stanniocalcin 1, Golgi membrane protein GP73.

15

Mainly downregulated during the secretory phase of the menstrual cycle:

Anaphase-promoting complex subunit 4, H1 histone family member 0, t-complex-associated-testis-expressed 1-like, regulator of G-protein signalling 9, islet cell autoantigen 1, metal-regulatory transcription factor 1, heat shock protein 70 kDa protein 1A, thyrotropin-releasing hormone, metallothionein 1E.

20

Among the most preferred targets for contrast agents for optical imaging of endometriosis are angiogenesis targets, adhesion molecules, estrogen receptors, progesterone receptors, Cathepsin H and Cathepsin S, aromatase, reductase, CD10, endoglin, haptoglobin and cyclin D2.

25

Generally, any targets that have been identified as possible targets for agents for treatment of endometriosis are potential targets also in optical imaging.

30

The preferred contrast agents are molecules with relatively low molecular weights. The molecular weight of preferred contrast agents is below 10000 Daltons, more preferably below 7000 Daltons.

35

The contrast agents are comprised of a vector that has affinity to an abnormally expressed target in endometriotic tissue, and an optical reporter. Thus viewed from one aspect the present invention provides a contrast agent of formula I:

V-L-R

(I)

wherein V is one or more vector moieties having affinity for one or more abnormally expressed target in endometriosis, L is a linker moiety or a bond and R is one or more reporter moieties detectable in optical imaging.

The vector has the ability to direct the contrast agent to a region of endometriosis.

The vector has affinity for the abnormally expressed target and preferably binds to the target. The reporter is detectable in an optical imaging procedure and the linker must couple vector to reporter, at least until the reporter has been delivered to the region of endometriosis and preferably until the imaging procedure has been completed.

The vector can generally be any type of molecules that have affinity for the abnormally expressed target. The molecules should be physiologically acceptable and should preferably have an acceptable degree of stability. The vectors can for instance be selected from the following group of compounds: peptides, peptoids/peptidomimetics, oligonucleotides, oligosaccharides, lipid-related compounds, like fatty acids, traditional organic drug-like small molecules, synthetic or semi-synthetic, and derivatives and mimetics thereof. When the target is an enzyme the vector may comprise an inhibitor of the enzyme. The vector of the contrast agent preferably has a molecular weight of less than 4500 Daltons and more preferably less than 2500 Daltons.

Contrast agents having affinity for more than one abnormally expressed target related to the disease is an aspect of the invention. Such contrast agents can comprise two or more different vectors or molecular subunits that target two or more different abnormally expressed targets.

Another possibility according to the present invention is that the contrast agent comprises one vector that is able to bind to more than one abnormally expressed target in endometriosis.


A contrast agent according to the present invention can also comprise more than one vector of same chemical composition that bind to the abnormally expressed biological target.

Some receptors are unique to endothelial cells and surrounding tissues. Examples of such receptors include growth factor receptors such as VEGF and adhesion molecules such as the integrin family of receptors. Peptides comprising the sequence 5 arginine-glycine-aspartic acid (RGD) are known to bind to a range of integrin receptors. Such RGD-type peptides constitute one group of vectors for targets associated with endometriosis.

Below are some examples of vectors having affinity for endometriosis-related 10 abnormally expressed targets:

Vectors for angiogenesis targets:


Vector I: Vectors for integrins – RGD-type peptides having affinity for $\alpha_v\beta_3$ and $\alpha_v\beta_5$ such as e.g.



15

Vector for progesterone receptors:

Vector II: Progesterone or a derivative thereof




20

Vectors for estrogen receptors:

Vector III: Estrogen, estrogen mimetics or a derivative thereof, e.g.

25




$n = 2-7$

Coupling takes place via the amine group

5

Vector for folate binding proteins:

Vector IV: Folate or a derivative thereof



10

A wide variety of linkers can be used. The linker component of the contrast agent is at its simplest a bond between the vector and the reporter moieties. In this aspect the reporter part of the molecule is directly bound to the molecule sub-unit that binds to the abnormally expressed target. More generally, however, the linker will provide a mono- or multi-molecular skeleton covalently or non-covalently linking one or more vectors to one or more reporters, e.g. a linear, cyclic, branched or reticulate molecular skeleton, or a molecular aggregate, with in-built or pendant groups which bind covalently or non-covalently, e.g. coordinatively, with the vector and reporter moieties. The linker group can be relatively large in order to build into the contrast agent optimal size or optimal shape or simply to improve the binding characteristics for the contrast agent to the abnormally expressed target in endometriotic tissue.

15

20

Thus, linking of a reporter unit to a desired vector may be achieved by covalent or non-covalent means, usually involving interaction with one or more functional groups located on the reporter and/or vector. Examples of chemically reactive functional groups which may be employed for this purpose include amino, hydroxyl, sulphydroxyl, carboxyl and carbonyl groups, as well as carbohydrate groups, vicinal diols, thioethers, 2-aminoalcohols, 2-aminothiols, guanidinyl, imidazolyl and phenolic groups.

25

The reporter is any moiety capable of detection either directly or indirectly in an optical imaging procedure. The reporter might be a light scatterer (e.g. a coloured or uncoloured particle), a light absorber or a light emitter. More preferably the reporter is

30

a dye such as a chromophore or a fluorescent compound. The dye part of the contrast agent can be any dye that interacts with light in the electromagnetic spectrum with wavelenghts from the ultraviolet light to the near infrared. Preferably, the contrast agent of the invention has fluorescent properties.

5

Preferred organic chromophoric and fluorophoric reporters include groups having an extensive delocalized electron system, eg. cyanines, merocyanines, indocyanines, phthalocyanines, naphthalocyanines, triphenylmethines, porphyrins, pyrilium dyes, thiapyrilium dyes, squarylium dyes, croconium dyes, azulenium dyes, indoanilines, benzophenoxazinium dyes, benzothiaphenothiazinium dyes, anthraquinones, napthoquinones, indathrenes, phthaloylacridones, trisphenoquinones, azo dyes, intramolecular and intermolecular charge-transfer dyes and dye complexes, tropes, tetrazines, bis(dithiolene) complexes, bis(benzene-dithiolate) complexes, iodoaniline dyes, bis(S,O-dithiolene) complexes. Fluorescent proteins, such as green fluorescent protein (GFP) and modifications of GFP that have different absorption/emission properties are also useful. Complexes of certain rare earth metals (e.g., europium, samarium, terbium or dysprosium) are used in certain contexts, as are fluorescent nanocrystals (quantum dots).

20

Particular examples of chromophores which may be used include fluorescein, sulforhodamine 101 (Texas Red), rhodamine B, rhodamine 6G, rhodamine 19, indocyanine green, Cy2, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, Cy7.5, Marina Blue, Pacific Blue, Oregon Green 488, Oregon Green 514, tetramethylrhodamine, and Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, and Alexa Fluor 750. Particularly preferred dyes are the cyanine dyes.

25

Particularly preferred are dyes which have absorption maxima in the visible or near infrared region, between 400 nm and 3 μm, particularly between 600 and 1300 nm.

30

Several relevant targets for endometriosis are enzymes. A contrast agent for optical imaging of endometriosis for targeting an enzyme can be an enzyme contrast agent substrate that can be transformed to a contrast agent product possessing different pharmacokinetic and/or pharmacodynamic properties from the contrast agent substrate. In this embodiment, the invention provides contrast agent substrates having affinity for an abnormally expressed enzyme, wherein the contrast agent

substrate changes pharmacodynamic and/or pharmacokinetic properties upon chemical modification into a contrast agent product in a specific enzymatic transformation, and thereby enabling detection of areas of disease upon a deviation in the enzyme activity from the normal. Typical differences in pharmacodynamic and/or pharmacokinetic properties can be binding properties to specific tissues, membrane penetration properties, protein binding and solubility properties.

Alternatively, if the abnormally expressed target for diagnosis of endometriosis is an enzyme, the contrast agent for optical imaging can be a dye molecule that directly binds to the enzyme. The contrast agent will have affinity for the abnormally expressed enzyme, and this may be used to identify tissue or cells with increased enzymatic activity.

In a further aspect of the invention, the contrast agent changes dye characteristics as a result of an enzymatic transformation. For example, a fluorescent dye reporter of the contrast agent is quenched (no fluorescence) by associated quencher groups until an enzymatic cleavage takes place, separating the dye from the quencher groups and resulting in fluorescence at the site of the abnormally expressed enzyme.

Another aspect of this part of the invention is that the dye may change colour, as e.g. a change in absorption and/or emission spectrum, as a result of an enzymatic transformation.

If the abnormally expressed target for diagnosis of endometriosis is a receptor or another non-catalytical target, the contrast agent for optical imaging can bind directly to the target and normally not change the dye characteristics.

Another aspect of the invention is contrast agents for optical imaging of endometriosis characterized by having affinity for more than one abnormally expressed target related to the disease. Such contrast agents can have two or more different vectors or molecular subunits that target two or more different abnormally expressed targets.

The preferred contrast agents of the present invention are soluble in water. This means that the preferred contrast agents have a solubility in water at pH 7.4 of at least 1 mg/ml.

The contrast agents of the present invention can be identified by random screening, for example by testing of affinity for abnormally expressed targets of a library of dye labelled compounds either prepared and tested as single compounds or by preparation and testing of mixture of compounds (a combinatorial approach).

5

The contrast agents of the invention can also be identified by use of technology within the field of intelligent drug design. One way to perform this is to use computer-based techniques (molecular modelling or other forms of computer-aided drug design) or use of knowledge about natural and exogenous ligands (vectors) for the abnormally expressed targets. The sources for exogenous ligands can for example be the chemical structures of therapeutic molecules for targeting the same target. One typical approach here will be to bind the dye chemical sub-unit to the targeting vector so that the binding properties of the vector are not reduced. This can be performed by linking the dye at the far end, away from the pharmacophore centre (the active targeting part of the molecule). Alternatively, random screening may be used to identify suitable vectors before labelling with a reporter.

20 The contrast agents of the invention are preferably not endogenous substances alone. Some endogenous substances, for instance estrogen, have certain fluorescent properties in themselves, but they are not likely to be sufficient for use in optical imaging. Endogenous substances combined with an optical reporter however, falls within the contrast agents of the invention.

25 The contrast agents of the invention are intended for use in optical imaging. Any method that forms an image for diagnosis of disease, follow up of disease development or for follow up of disease treatment based on interaction with light in the electromagnetic spectrum from ultraviolet to near infrared radiation fall within the term optical imaging. Optical imaging further includes all methods from direct visualization without use of any device and use of devices such as various scopes, 30 catheters and optical imaging equipment, for example computer based hardware for tomographic presentations. The contrast agents will be useful with optical imaging modalities and measurement techniques including, but not limited to: luminescence imaging; endoscopy; fluorescence endoscopy; optical coherence tomography; transmittance imaging; time resolved transmittance imaging; confocal imaging; 35 nonlinear microscopy; photoacoustic imaging; acousto-optical imaging; spectroscopy; reflectance spectroscopy; interferometry; coherence interferometry; diffuse optical tomography and fluorescence mediated diffuse optical tomography (continuous


wave, time domain and frequency domain systems), and measurement of light scattering, absorption, polarisation, luminescence, fluorescence lifetime, quantum yield, and quenching.

5 Examples of contrast agent for optical imaging of endometriosis according to the invention are shown below with some accompanied suggested synthetic routes:

Contrast agents with affinity for angiogenesis:

Compound 1:

10




Vector: RGD-type peptide

Linker: PEG-moiety

Reporter: Fluorescein


15 Compound II:



Wherein the reporter is a 7-hydroxycoumarine derivative.

Contrast agent with affinity for progesterone receptors:


20 Compound III:



Wherein progesterone is coupled to a 7-hydroxycoumarine derivative (Acid (A)) via a alkyl-linker.


5

Acid (A):



10 Contrast agent with affinity for estrogen receptors:


Compound IV:



15 The compound has been described by Fevig et al in J. Med. Chem. 1987, 30, 156-165 but not in the context of optical imaging of endometriosis. The compound consists of two estrogen derivatives linked to a NIR dye.

20


Compound V:



The compound has been described by Koulocheri et al in Eur. J. Org. Chem 2001,
5 1723-1729 but not in the context of optical imaging of endometriosis. The compound
is a 2,3-bis(4-hydroxyphenyl)indole having good estrogen binding properties and an
intense long-wavelength fluorescent emission.

Contrast agent with affinity for folate binding proteins:

Compound VI:



5

This complex comprising a NIR dye, a PEG moiety and a folate vector has been described in Bioconjugate Chem., Vol. 14, Ni.3, 2003, but not in the context of optical imaging of endometriosis.

10 A further embodiment is use of contrast agents of the invention for optical imaging of endometriosis, that is, for diagnosis of endometriosis, for follow up of the progress in endometriosis development or for follow up the treatment of endometriosis. In the context of this invention diagnosis includes screening of selected populations, early detection, biopsy guidance, characterisation, staging, grading, therapy efficacy
15 monitoring, long-term follow-up of relapse and surgical guidance.

Still another embodiment of the invention is a method of optical imaging for diagnosis of endometriosis using the contrast agents as described.

Still another embodiment of the invention is a method of optical imaging for diagnosis, to follow up the progress of endometriosis development and to follow up the treatment of endometriosis.

- 5 One aspect of these methods is to administer the present contrast agents and follow the accumulation and elimination directly visually during surgery. Another aspect of these methods is to administer the present contrast agents and perform visual diagnosis through a laparoscope.
- 10 Still another aspect of the present invention is to administer the present contrast agents and perform the image diagnosis using computerized equipment as for example a tomograph.

Still another embodiment of the invention is use of a contrast agent as described for
15 the manufacture of a diagnostic agent for use in a method of optical imaging of endometriosis involving administration of said diagnostic agent to an animate body and generation of an image of at least part of said body.

Still another embodiment of the invention is pharmaceutical compositions comprising
20 one or more contrast agents as described or pharmaceutically acceptable salts thereof for optical imaging for diagnosis of endometriosis, for follow up progress of endometriosis development or for follow up the treatment of endometriosis. The diagnostic agents of the present invention may be formulated in conventional pharmaceutical or veterinary parenteral administration forms, e.g. suspensions,
25 dispersions, etc., for example in an aqueous vehicle such as water for injections. Such compositions may further contain pharmaceutically acceptable diluents and excipients and formulation aids, for example stabilizers, antioxidants, osmolality adjusting agents, buffers, pH adjusting agents, etc. The most preferred formulation is a sterile solution for intravascular administration or for direct injection into area of
30 interest. Where the agent is formulated in a ready-to-use form for parenteral administration, the carrier medium is preferably isotonic or somewhat hypertonic.

The dosage of the optical diagnostic agents of the invention will depend upon the clinical indication, choice of contrast agent and method of administration. In general,
35 however dosages will be between 10 µg and 5 grams for an adult human.

While the present invention is particularly suitable for methods involving parenteral administration of the contrast agent, e.g. into the vasculature or directly into an organ of muscle tissue, intravenous administration being especially preferred, it is also applicable where administration is not via a parenteral route, e.g. where

5 administration is transdermal, nasal, sub-lingual or is into an externally voiding body cavity, e.g. the gi tract, the bladder, the uterus or the vagina. The present invention is deemed to extend to cover such administration.

The following examples are illustrative only and not intended to be limiting. Other
10 features and advantages of the invention will be apparent from the detailed description and from the claims.

Examples**Example 1. Contrast agent with affinity for folate binding protein. Synthesis of folic acid – fluorescein linker conjugate**

5

Step 1

Folic acid dehydrate (1.0 g) is mixed with toluene (500 ml) and heated to 110°C. The mixture is cooled to 50°C and evaporated to dryness. Folic acid anhydride is isolated.

10 **Step 2**

Folic acid anhydride (441 mg, 1 mmol) and 1,3-dicyclohexylcarbodiimide (DCC) (226 mg, 1.1 mmol) are dissolved in DMF (30 ml). The mixture is cooled to 0°C and a solution of 2,2'-ethylenedioxybis(ethylamine) (296 mg, 2 mmol) and DMAP (30 mg) in DMF (10 ml) is added. The mixture is stirred for 1 hour at 0°C and then stirred for 15 72 hours at ambient temperature. The solution is evaporated and the conjugate between folic acid and the bisamide is isolated as monoamide by chromatography (silica, chloroform and methanol).

Step 3

20 5(6) – Carboxyfluorescein (188 mg, 0.5 mmol) and dicyclohexylcarbodiimide (113 mg, 0.55 mmol) are dissolved in DMF (20ml). The mixture is cooled to 0°C and a solution of the monoamide from step 2 above (286 mg, 0.5 mmol) and DMAP (15 mg) in DMF (5 ml) is added. The mixture is stirred for 1 hour at 0°C and then stirred for 72 hours at ambient temperature. The solution is evaporated and the final 25 conjugate is isolated by chromatography (silica, chloroform and methanol).

Example 2. Contrast agent for mapping of matrix metalloproteinase (MMP). Synthesis of fluorescein–Cys-Gly-Pro-Leu-Gly-Leu-Leu-Ala-Arg-OH linker conjugate

30

Step 1

The peptide component was synthesised on an ABI 433A automatic peptide synthesiser starting with Fmoc –Arg (Pmc) –wang resin on a 0.1mmol scale using 1mmol amino acid cartridges. The amino acids were pre-activated using HBTU 35 before coupling. An aliquot of the peptide resin was then transferred to a clean round bottom flask an N-methyl morpholine (1 mmol) in DMF (5 ml) added followed by

chloroacetyl chloride (1mmol). The mixture was gently shaken until Kaiser test negative. The resin was extensively washed with DMF.


Step 2

- 5 5(6)-carboxyfluorescein (188 mg, 0.5 mmol) and dicyclohexylcarbodiimide (113 mg, 0.55 mmol) are dissolved in DMF (20 ml). The mixture is stirred for 2 hours and cooled to 0°C. A solution of hexamethylenediamine (116 mg, 1 mmol) and DMAP (30 mg) in DMF is added and the mixture is stirred at ambient temperature for 72 hours. The solution is evaporated and the conjugate between carboxyfluorescein and
- 10 hexamethylene-amine is isolated as monoamide by chromatography (silica, chloroform and methanol).

Step 3

- The resin from step 1 is suspended in DMF (5 ml) and amide-amine conjugate from
- 15 step 2 (0.5 mmol) pre-dissolved in DMF (5ml) containing triethylamine (0.5 mmol) is added. The mixture is heated to 50°C for 16 hours then excess reagents filtered off, following extensive washing with DMF, DCM and diethyl ether then air drying. The product is treated with TFA containing TIS (5%), H₂O (5%), and phenol (2.5%) for 2 hours.
- 20 Excess TFA is removed *in vacuo* and the peptide is precipitated by the addition of diethyl ether. The crude peptide conjugate is purified by preparative HPLC C C-18, acetonitril, TFA, water).

Example 3. Contrast agent for mapping of estrogen receptors; Cy 5.5 linked to estrogen derivative



(2R, 3S)-2,3-bis[4-[(tert-butyldimethylsilyl)oxy]-phenyl]pentyl-5-aminopenylsulfide is prepared according to T.L. Fevig et al in J.Med.Chem 1987, 30, 156-165.

- 5 The above amine (1 mmol) and Cy 5.5 NHS ester (1 mmol) are dissolved in dimethylformamide (25 ml). N-methylmorpholine (300 μ l) is added and the mixture stirred at ambient temperature for 4 days. The mixture is evaporated and the coupling product is isolated by flash chromoatography (silica, hexane and ethyl acetate). This product is dissolved in ethylacetate and treated with
- 10 paratoluenesulphonic acid (25 mmol). The solvent is evaporated and the oily mixture is heated at 40 °C for 30 minutes. The product is isolated by flash chromatography (silica, hexane and ethyl acetate).

Example 4. Contrast agent with affinity for integrins: RGD peptide linked to


- 15 **Cy5.5**

Step 1. Assembly of amino acids

- The peptide sequence Asp-D-Phe-Lys-Arg-Gly was assembled on an Applied Biosystems 433A peptide synthesizer starting with 0.25 mmol Fmoc-Gly-SASRIN resin. An excess of 1 mmol pre-activated amino acids (using HBTU; O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosohate) was applied in the coupling steps. The cleavage of the fully protected peptide from the resins was carried out by treatment of the resin with three portions of 35 mL of 1 % trifluoroacetic acid (TFA) in dichloromethane (DCM) for 5 minutes each. The filtrates containing the peptide was immediately neutralised with 2 % piperidine in DCM. The organics were extracted with water (3 x 100 mL), dried with MgSO₄ and evaporated *in vacuo*. Diethyl ether was added to the residue and the precipitate washed with ether and air-dried affording 30 mg of crude protected peptide. The product was analysed by analytical
- 25 HPLC (conditions: Gradient, 20-70 % B over 10 min where A = H₂O/0.1 % TFA and B = CH₃CN/0.1 % TFA; flow, 2 mL/min; column, Phenomenex Luna 3 μ 5 x 4.6 mm; detection, UV 214 nm; product retention time 7.58 min). Further product characterisation was carried out using electrospray mass spectrometry (MH⁺ calculated, 1044.5; MH⁺ found, 1044.4).

Step 2. N-C Cyclisation

c[-Asp-D-Phe-Lys-Arg-Gly-]




5

30 mg of the fully protected peptide, 16 mg of PyAOP, 4 mg of HOAt and 6 μ L of N-methylmorpholine (NMM) were dissolved in dimethylformamide/DCM (1:1) and stirred over night. The mixture was evaporated *in vacuo* and diethyl ether added to the residue. The precipitate was washed with ether and air-dried. The crude cyclic 10 fully protected peptide was treated with a solution of 25 mL TFA containing 5 % water, 5 % triisopropylsilane and 2.5 % phenol for two hours. TFA was evaporated *in vacuo* and diethyl ether added to the residue. The precipitate was washed with ether and air-dried. Purification by preparative RP-HPLC (0-30 % B over 40 min, where A = H₂O/0.1 % TFA and B = CH₃CN/0.1 % TFA, at a flow rate of 10 mL/min on a 15 Phenomenex Luna 5 μ C18 250 x 21.20 mm column) of the crude material afforded 2.3 mg pure product peptide. The pure product was analysed by analytical HPLC (conditions: Gradient, 0-15 % B over 10 min where A = H₂O/0.1 % TFA and B = CH₃CN/0.1 % TFA; flow, 2 mL/min; column, Phenomenex Luna 3 μ 5 x 4.6 mm; detection, UV 214 nm; product retention time 6.97 min). Further product 20 characterisation was carried out using electrospray mass spectrometry (MH⁺ calculated, 604.3; MH⁺ found, 604.4).

Step 3 . Conjugation of Cy5.5 to RGD peptide

25 c[-Asp-D-Phe-Lys(Cy5.5)-Arg-Gly-]



0.6 mg of the RGD peptide, 1.7 mg of Cy5.5 mono NHS ester and 5 μ L of NMM were dissolved in 1 mL of dimethylformamide (DMF) and the reaction mixture stirred for 2 hrs. Diethyl ether was added to the DMF solution and the blue precipitate washed 5 with diethyl ether and air-dried affording 0.7 mg of crude RGD peptide conjugated to Cy5.5. The pure product was analysed by analytical HPLC (conditions: Gradient, 5-50 % B over 10 min where A = H₂O/0.1 % TFA and B = CH₃CN/0.1 % TFA; flow, 0.3 mL/min; column, Phenomenex Luna 3 μ 5 x 2 mm; detection, UV 214 nm; product retention time 8.32 min). Further product characterisation was carried out using 10 electrospray mass spectrometry (MH⁺ calculated, 1502.5; MH⁺ found, 1502.6).

Claims:

1. An optical imaging contrast agent with affinity for an abnormally expressed biological target associated with endometrioses.
- 5 2. A contrast agent as claimed in claim 1 with molecular weight below 10000 Daltons.
3. A contrast agent as claimed in claim 1 or 2 of formula I
V-L-R (I)
10 wherein V is one or more vector moieties having affinity for an abnormally expressed target in endometriosis, L is a linker moiety or a bond and R is one or more reporter moieties detectable in vivo optical imaging.
4. A contrast agent as claimed in any of claims 1 to 3 comprising a contrast agent substrate, wherein the target is an abnormally expressed enzyme, such that the contrast agent changes pharmacodynamic properties and/or pharmacokinetic properties upon a chemical modification from a contrast agent substrate to a contrast agent product upon a specific enzymatic transformation.
- 15 5. A contrast agent as claimed in any of claims 1 to 4 having affinity for any of the targets selected from angiogenesis targets, adhesion molecules, estrogen receptors, progesterone receptors, Cathepsin H and Cathepsin S, aromatase, reductase, CD10, endoglin, haptoglobin and cyclin D2.
- 20 6. A contrast agent as claimed in claims 3 or 4 wherein V is selected from peptides, peptoid moieties, oligonucleotides, oligosaccharides and lipid-related compounds and traditional organic drug-like small molecules.
- 25 7. A contrast agent as claimed in any of claims 3-6 wherein R is a dye that interacts with light in the wavelength region from the ultraviolet to the infrared part of the electromagnetic spectrum.
- 30 8. A pharmaceutical composition for optical imaging for diagnosis of endometriosis, for follow up of progress of endometriosis, or for follow up of treatment of endometriosis, comprising a contrast agent as defined in any of claims 1 to 7 together with at least one pharmaceutically acceptable carrier or excipient.

9. Use of a contrast agent as claimed in any of claims 1 to 7 for the manufacture of a diagnostic agent for use in a method of optical imaging of endometriosis involving administration of said diagnostic agent to an animate subject and generation of an image of at least part of said subject.

5

10. A method of generating an optical image of an animate subject involving administering a contrast agent to said subject and generating an optical image of at least a part of said subject to which said contrast agent has distributed, characterized in that as said contrast agent is used a contrast agent as defined in any of claims

10 1 to 7.

11. Method as claimed in claim 10 for diagnosis of endometriosis, for follow up the progress of endometriosis development or for follow up treatment of endometriosis using a contrast agent as defined in any of claims 1 to 7.

15

12. Use of a contrast agent as defined in any of claims 1 to 7 for optical imaging of endometriosis.

SEQUENCE LISTING

<110> Amersham Health AS

5 <120> Optical imaging of endometriosis

<130> PN0369

<150> NO 20034351

10 <151> 2003-09-29

<160> 5

<170> PatentIn version 3.1

15 <210> 1

<211> 9

<212> PRT

<213> Artificial sequence

20 <220>

<223> Synthesised peptide

<400> 1

25

Cys Gly Pro Leu Gly Leu Leu Ala Arg

1 5

30 <210> 2

<211> 5

<212> PRT

<213> Artificial sequence

35 <220>

<223> Syntehsised peptide

<400> 2

40 Asp Phe Lys Arg Gly

1 5

<210> 3

45 <211> 5

<212> PRT

<213> Artificial sequence

<220>

50 <223> Synthesised peptide

<220>

<221> MISC_FEATURE

<222> (1)..(5)

55 <223> Cyclisation of peptide through peptide bond between amino acid 1

and 5

<400> 3

5

Asp Phe Lys Arg Gly

1 5

10 <210> 4

<211> 8

<212> PRT

<213> Artificial sequence

15 <220>

<223> Synthesised peptide

<400> 4

20 Asp Cys Arg Gly Asp Cys Phe Cys

1 5

25 <210> 5

<211> 8

<212> PRT

<213> Artificial sequence

30 <220>

<223> Synthesised peptide

<220>

<221> DISULFID

<222> (2)..(6)

35 <223> Disulphide bond between amino acids 2 and 6

40 <220>

<221> THIOETH

<222> (1)..(8)

<223> Thioether bridge between amino acids 1 and 8

45 <400> 5

Asp Cys Arg Gly Asp Cys Phe Cys

1 5

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number
WO 2005/030265 A3

(51) International Patent Classification⁷: **A61K 49/00**

(21) International Application Number:
PCT/NO2004/000286

(22) International Filing Date:
28 September 2004 (28.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20034351 29 September 2003 (29.09.2003) NO

(71) Applicant (for all designated States except US): **AMER-SHAM HEALTH AS** [NO/NO]; Intellectual Property Dept., P.O. Box 4220 Nydalen, Nycoveien 1-2, N-0401 Oslo (NO).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KLAVENESS, Jo** [NO/NO]; Midtåsen 5, N-1166 Oslo (NO). **JOHANNESEN, Edvin** [NO/NO]; Amersham Health AS, P.O. Box 4220 Nydalen, Nycoveien 1-2, N-0401 Oslo (NO). **TOLLESHAUG, Helge** [NO/NO]; Amersham Health AS, P.O. Box 4220 Nydalen, Nycoveien 1-2, N-0401 Oslo (NO).

(74) Agents: **WULFF, Marianne, Weiby et al.**; Amersham Health AS, P.O. Box 4220 Nydalen, Nycoveien 1-2, N-0401 Oslo (NO).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
7 July 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/030265 A3

(54) Title: OPTICAL IMAGING OF ENDOMETRIOSIS

(57) **Abstract:** The invention provides contrast agents for optical imaging of endometriosis in patients. The contrast agent may be used in diagnosis of endometriosis, for follow-up of progress in disease development, and for follow-up of treatment of endometriosis. Further, the invention provides methods for optical imaging of endometriosis. The contrast agent has affinity for an abnormally expressed target associated with endometriosis. By abnormally expressed, is meant that the target is either overexpressed or downregulated. Endometriotic tissue containing a downregulated target may be identified by a low amount of bound contrast agent compared to normal tissue. In this situation, the amount of contrast agent should be less than 50% of that in normal tissue, preferably less than 10%.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/N02004/000286

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K49/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, CHEM ABS Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MALIK E ET AL: "Fluorescence diagnosis of endometriosis using 5-aminolevulinic acid" SURGICAL ENDOSCOPY, vol. 14, no. 5, 2000, pages 452-455, XP002326510 ISSN: 0930-2794 abstract page 452, right-hand column page 454; tables 1,2 page 455, right-hand column, last paragraph</p> <p>-----</p> <p>WO 01/23005 A (SCHERING AKTIENGESELLSCHAFT; SCHIRNER, MICHAEL; LICHA, KAI; DINKELBORG) 5 April 2001 (2001-04-05) page 12, line 18 - line 26 claim 14</p> <p>-----</p> <p>-/-</p>	1,2,8-11
X		1,3-12

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

28 April 2005

Date of mailing of the international search report

10/05/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Dullaart, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/NO2004/000286

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003/162234 A1 (JALLAD KARIM N ET AL) 28 August 2003 (2003-08-28) claims -----	1-12
X	WO 93/02192 A (REPLIGEN CORPORATION) 4 February 1993 (1993-02-04) page 1, line 24 - line 28 examples 9,10 -----	1-12
X	WO 03/079015 A (VISEN MEDICAL, INC; POSS, KIRTLAND, G; MADDEN, KAREN, N; JONES, ELLA;) 25 September 2003 (2003-09-25) claims -----	1-12
E	WO 2005/012901 A (AMERSHAM BIOSCIENCES UK LIMITED; WHATELEY, JOHN, GERARD; ISMAIL, RAHMA) 10 February 2005 (2005-02-10) the whole document -----	1-12
E	WO 2005/030266 A (AMERSHAM HEALTH AS; KLAVENESS, JO; JOHANNESEN, EDVIN; TOLLESHAUG, HELG) 7 April 2005 (2005-04-07) example 5 -----	1-12
P, X	US 2004/053823 A1 (SMITH JEFFREY W ET AL) 18 March 2004 (2004-03-18) examples II-IV claims -----	1-12
Y	SOUKOS, N. S. ET AL: "Monoclonal antibody-tagged receptor-targeted contrast agents for detection of cancers" PROCEEDINGS OF SPIE-THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING , 4259(BIOMARKERS AND BIOLOGICAL SPECTRA IMAGING), 115-128 CODEN: PSISDG; ISSN: 0277-786X, 2001, XP002326511 page 118, paragraph 2.7 - paragraph 2.8 page 120, paragraph 3.3 - page 125 -----	1-12
X	KANG, H. W. ET AL: "Targeting of MPEG-protected polyamino acid carrier to human E-selectin in vitro" AMINO ACIDS , 23(1-3), 301-308 CODEN: AACIE6; ISSN: 0939-4451, 2002, XP002326512 abstract table 1 figures 1-5 ----- -/-	1,3-12

INTERNATIONAL SEARCH REPORT

International Application No
PCT/N02004/000286

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ZHOU, LANLAN ET AL: "NIR imaging the delivery of cathepsin B probe to breast tumors" PROCEEDINGS OF SPIE—THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING, 4955(OPTICAL TOMOGRAPHY AND SPECTROSCOPY OF TISSUE V), 505–512 CODEN: PSISDG; ISSN: 0277-786X, 2003, XP002326513 abstract figures 1,3-6; table 2	1-12
O,Y	& OPTICAL TOMOGRAPHY AND SPECTROSCOPY OF TISSUE V, 26 January 2003 (2003-01-26), – 29 January 2003 (2003-01-29) SAN JOSE, CA, USA ----	1-12
P,Y	KE, SHI ET AL: "Near-Infrared Optical Imaging of Epidermal Growth Factor Receptor in Breast Cancer Xenografts" CANCER RESEARCH, 63(22), 7870–7875 CODEN: CNREA8; ISSN: 0008-5472, 2003, XP002326514 abstract ----	1-12
P,Y	CITRIN, DEBORAH ET AL: "In vivo tumor imaging using a near-infrared-labeled endostatin molecule" INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS, 58(2), 536–541 CODEN: IOBPD3; ISSN: 0360-3016, 2004, XP002326515 abstract page 538, paragraph RESULTS figures 1,2	1-12
O,Y	& ICTR 2003, 2ND INTERNATIONAL CONFERENCE ON TRANSLATIONAL RESEARCH AND PRECLINICAL STRATEGIES IN RADIATION ONCOLOGY, 16 March 2003 (2003-03-16), – 19 March 2003 (2003-03-19) LUGANO, CH ----	1-12
P,Y	CITRIN, DEBORAH ET AL: "In vivo tumor imaging in mice with near-infrared labeled endostatin" MOLECULAR CANCER THERAPEUTICS, 3(4), 481–488 CODEN: MCTOCF; ISSN: 1535-7163, 2004, XP002326516 abstract ----	1-12
X	MOON WOO KYUNG ET AL: "Enhanced tumor detection using a folate receptor-targeted near-infrared fluorochrome conjugate." BIOCONJUGATE CHEMISTRY, vol. 14, no. 3, 1 May 2003 (2003-05-01), pages 539–545, XP002326517 ISSN: 1043-1802 figure 1 -----	1-12
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/NO2004/000286

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MALIK E ET AL: "Angiogenic activity of fluorescent peritoneal fluid in patients with endometriosis" GEBURTSHILFE UND FRAUENHEILKUNDE, vol. 59, no. 12, December 1999 (1999-12), pages 622-625, XP008045889 ISSN: 0016-5751 abstract -----	1,2
Y	GARCIA-VELASCO JUAN A ET AL: "Interleukin-8 stimulates the adhesion of endometrial stromal cells to fibronectin" FERTILITY AND STERILITY, vol. 72, no. 2, August 1999 (1999-08), pages 336-340, XP002326518 ISSN: 0015-0282 abstract page 337, right-hand column -----	1-12
T	CHEN WEI-TSUNG ET AL: "Arthritis imaging using a near-infrared fluorescence folate-targeted probe." ARTHRITIS RESEARCH & THERAPY. 2005, vol. 7, no. 2, 2005, pages R310-R317, XP008045879 ISSN: 1478-6362 the whole document -----	1-12
Y	KATS ROUSLAN ET AL: "Macrophage migration inhibitory factor is markedly expressed in active and early-stage endometriotic lesions." THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. FEB 2002, vol. 87, no. 2, February 2002 (2002-02), pages 883-889, XP002326519 ISSN: 0021-972X abstract -----	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/N02004/000286

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0123005	A 05-04-2001	DE 19947559 A1 AU 779026 B2 AU 6702600 A BG 106528 A BR 0014192 A CA 2385593 A1 CN 1376074 A CZ 20020991 A3 EE 200200152 A WO 0123005 A1 EP 1214099 A1 HU 0202625 A2 JP 2003510294 T MX PA02002639 A NO 20021441 A NZ 517944 A PL 354027 A1 SK 3972002 A3 ZA 200203225 A		19-04-2001 06-01-2005 30-04-2001 29-12-2002 21-05-2002 05-04-2001 23-10-2002 12-06-2002 15-04-2003 05-04-2001 19-06-2002 28-12-2002 18-03-2003 30-07-2002 15-05-2002 25-06-2004 15-12-2003 10-09-2002 23-07-2003
US 2003162234	A1 28-08-2003	US 2004136910 A1		15-07-2004
WO 9302192	A 04-02-1993	CA 2113206 A1 EP 0594749 A1 JP 6509116 T WO 9302192 A1		04-02-1993 04-05-1994 13-10-1994 04-02-1993
WO 03079015	A 25-09-2003	AU 2003225763 A1 EP 1485716 A1 WO 03079015 A1		29-09-2003 15-12-2004 25-09-2003
WO 2005012901	A 10-02-2005	WO 2005012901 A2		10-02-2005
WO 2005030266	A 07-04-2005	WO 2005030266 A2		07-04-2005
US 2004053823	A1 18-03-2004	NONE		